Physician profile
Mark A Macnealy
NPI 1861838922
$5,716.12
in general payments reported to CMS, 2019-2025
21 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $379 · 2021: $1,420 · 2022: $1,139 · 2023: $2,577 · 2024: $79.49 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775 · Education: $2.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.07 |
| Education | $2.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $972.85 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $822.66 | 2020-2023 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $737.35 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $534.61 | 2021-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $456.89 | 2021-2023 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $415.22 | 2021-2023 | Austedo, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $354.20 | 2020-2023 | Ingrezza |
| Alkermes, INC. | $320.85 | 2021-2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $310.52 | 2023 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $197.72 | 2020-2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $176.06 | 2023 | Quviviq |
| Abbvie INC. | $163.81 | 2022-2025 | |
| Lundbeck LLC | $92.84 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $29.47 | 2022-2023 | Belsomra |
| Corium, LLC | $28.11 | 2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $26.83 | 2021-2022 | |
| Allergan, INC. | $22.60 | 2020 | |
| Avanir Pharmaceuticals, INC. | $14.50 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.80 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $12.69 | 2022 | |
| Bausch Health US, LLC | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Macnealy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.